Study of fluticasone propionate via a new inhaler in severe asthma

• Research type

  Research Study

• Full title

  A randomised double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different total daily doses of fluticasone propionate inhaled from a new dry powder inhaler in subjects with severe persistent asthma requiring oral corticosteroid therapy

• IRAS ID

  107245

• Contact name

  Adel Mansur

• Sponsor organisation

  Vectura Limited

• Eudract number

  2011-005030-19

• ISRCTN Number

  N/A

• Research summary

  Fluticasone propionate is a widely prescribed drug for patients with respiratory diseases, particularly for the maintenance treatment of asthma. Vectura Limited has developed a new dry powder inhaler to deliver fluticasone propionate into subjects with severe persistent asthma who require oral corticosteroid therapy. The aim of this study is to test the safety and efficacy of this new product.

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  12/EM/0242

• Date of REC Opinion

  17 Aug 2012

• REC opinion

  Favourable Opinion